Trial Profile
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALCHEMIST; ALCHEMIST-EGFR
- 26 May 2021 Planned primary completion date changed from 4 Nov 2021 to 10 Oct 2026.
- 21 Jan 2021 Status changed from suspended to active, no longer recruiting.
- 23 Dec 2020 Status changed from recruiting to suspended.